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Abstract
Background: To determine the diagnostic efficacy of ultrasonographic malignancy risk features (UMRFs) in follicular
lesions (FL) in a population with low risk of malignancy in FL and to compare it with a similar analysis in a group of
patients with unequivocal cytology (UC): benign lesion (BL) or malignant neoplasm (MN).
Methods: Presence of UMRFs (hypoechogenicity, solid echostructure, taller-than-wide shape, pathological
vascularization, irregular margins, microcalcifications and macrocalcifications) and their sets were assessed in
322 FL: 202 follicular lesions of undetermined significance (FLUS) and 120 suspicious for follicular neoplasm
(SFN) and 300 nodules with UC: 200 BL and 100 MN, subsequently evaluated histopathologically.
Results: Cancers were confirmed in 100% nodules in MN group (89.0% of them were papillary carcinomas - PTC), in
6.4% FLUS nodules (69.2% PTC), and in 10.8% SFN nodules (30.8% PTC). In the UC group all UMRFs occurred more
frequently in cancers than in benign lesions. In the FL group only calcifications were found in cancers more
frequently – macro and microcalcifications together: 34.6 vs. 11.5% (p = 0.001) and isolated macrocalcifications:
26.0 vs. 6.8% (p = 0.001); the presence of those features increased the basic risk of malignancy in FL more than 2
times. The presence of at least 2 of the following URMFs: hypoechogenicity, solid echostructure, any type of
calcifications and suspected shape, additionally improved sensitivity.
Conclusions: Evaluation of UMRFs in FLs is less effective than in nodules with UC, and its effectiveness decreases
parallel to the decrease in percentage of PTCs among malignant neoplasms and to the increase of the percentage of
adenomas among benign nodules. The presence of macrocalcifications in such FLs significantly increases the basic risk
of malignancy in these nodules.
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Background
Preoperative diagnostics of thyroid nodules is still a subject
of investigation. Among others, the usefulness of classic
ultrasonography is evaluated in the selection of nodules for
fine-needle aspiration biopsy (FNA) or in assisting clinical
decision making in patients with equivocal FNA results –
mainly in patients with follicular lesions (FL) [1–10].
Indications for nodule biopsy are based largely on the
presence of ultrasound malignancy risk features (UMRFs).
These features separately do not have a satisfying sensitiv-
ity and specificity, so the use of various sets of the features
is proposed. There is however some disagreement on both
the significance of particular features and their optimal
association. The American Thyroid Association (ATA)
recommends a several grade scale for the assessment of
ultrasonographic malignancy risk in nodules [11]. This
scale is based mainly on the presence of high specificity
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UMRFs in hypoechoic nodules. These features include
irregular margins, microcalcifications, taller than wide
shape, disrupted rim calcifications or evidence of extra-
thyroidal extension. The American Society of Radiolo-
gists in Ultrasound additionally enumerates coarse
calcifications among UMRFs [12], while The British
Thyroid Association adds intranodular vascularity and
proposes their own system to interpret various sets of
UMRFs [13].
Particular discrepancies regard effectiveness of the ana-
lysis of sonographic features to estimate risk of malignancy
in two categories of FL: follicular lesion of undetermined
significance - FLUS –group III of cytological diagnoses
in the Bethesda system and suspicious for follicular
neoplasm – SFN –group IV of cytological diagnoses
[1, 2, 7, 10, 14–19]. For the patients with FLUS in
cytological outcome this issue is of particular import-
ance, as this result has not been established as a direct
indication for surgical treatment [11, 20]. In some reports
a high positive predictive value was observed in the pres-
ence of UMRFs in FLUS nodule, but they came from the
centres with high risk of malignancy in such nodules and
high fraction of papillary carcinomas (PTC) among ma-
lignant tumours found in FLUS [3, 5, 14–16, 19]. Other
reports do not confirm those observations [2, 6]. There
is limited data on this subject, especially with respect
to cytological data verified against histopathological ex-
aminations, which relate to populations with low risk
of malignancy in FLUS and SFN nodules. In such popu-
lations FLUS and SFN diagnoses mainly correspond to
non-neoplastic FL developing in a consequence of iod-
ine shortage. The ratio of PTC to follicular carcinoma
(FTC) is also lower in these populations [21]. These
factors can influence the results of assessments of the
usefulness of UMRFs and may be an important cause
of the described discrepancies. Unfortunately, they are
considered only in a minority of studies despite data
indicating that PTC and FTC differ from each other in
ultrasound imaging [22]. In our centre, where cyto-
logical diagnostics is performed in the population
which had been exposed to iodine deficiency until only
20 years ago [23], the risk of malignancy in FLUS nod-
ules, as determined with the results of histopatho-
logical examination, does not exceed 6% [24, 25]. This
risk is concordant with the assumptions made when
the FLUS category was created and is significantly
lower than that in SFN nodules, which show a 10-20%
malignancy risk [25, 26].
Thus, the aim of our study was to determine the diag-
nostic efficacy of UMRFs analysis in patients with FL
and a relatively low risk of malignancy and to compare it
with the results of similar analysis in the group of pa-
tients with unequivocal FNA outcomes: benign lesion
(BL), malignant neoplasm (MN).
Methods
Examined patients
FNA and ultrasound imaging were performed in one
centre in years 2010–2015 in patients referred by endo-
crinologists from outpatient clinics. Analysis of UMRFs
was done prospectively. The presence of particular UMRFs
was assessed by 3 experienced (>10 years) sonographers
directly before FNA. Biopsy was performed only on thyroid
nodules with a diameter of at least 5 mm, which had at
least one malignancy risk factor (ultrasonographic or clin-
ical), or nodules > 1 cm in the absence of more suspicious
lesions. Smears were fixed in 95% ethanol solution and
stained with hematoxylin and eosin. A detailed description
of the FNA procedure was presented in our earlier report
[24]. Results of the FNA were classified into 6 groups de-
fined in the Bethesda system [20].
The category of biopsy result was the basis for assigning
a nodule into the analysis. The study included all FLUS
and SFN nodules with full ultrasound imaging data and
the results of the postoperative histopathological exam-
ination. Diagnosis of SFN was formulated when the
specimen contained a monotonous population of TFC
arranged in three-dimensional groups and microfollicles
with nuclear overlapping and crowding in a background
of little to no colloid. The diagnosis of FLUS was made
when the specimen showed features of both a benign thy-
roid nodule and a follicular neoplasm. In 4 cases speci-
mens with limited cellularity but with nuclear atypia were
also classified into category III of the Bethesda system.
Additionally, a similar number was analysed in subsequent
nodules with unequivocal cytology (UC): BL or MN,
which were eventually subjected to surgical treatment. In
the case of diagnosis of BL or FLUS surgical treatment
was performed due to the large size of the nodule or based
on the patient’s preference. In some cases (38, 18.8%) of
FLUS nodules, surgical treatment was performed after
control FNA, which gave the same diagnosis or result
belonging to the category of higher risk of malignancy.
Eventually the analysis was performed in 322 FL, in-
cluding 202 FLUS and 120 SFN as well as in 300 UC
nodules, including 200 BL and 100 MN (Table 1). Patients
previously treated with surgery or radioiodine were ex-
cluded from the study.
Analysis of UMRFs
The US examinations were accomplished using the Aloka
Prosound Alpha 7 ultrasonograph, ALOKA co. Ltd., Tokyo,
Japan with a 7.5–14 MHz linear transducer. The presence
of the following UMRFs was assessed: 1) hypoechogenicity
or marked hypoechogenicity (compared with the surround-
ing thyroid or strap muscles), 2) solid echostructure (<25%
cystic), 3) the cumulative presence of the features 1. and 2.
4) more-tall-than-wide shape (measured on a transverse
view), 5) pathological vascularization - chaotic intranodular
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vascular spots, 6) suspicious margins - irregular or suggest-
ing extrathyroidal extension, 7) calcifications with separate
consideration for microcalcifications (7a) – defined as calci-
fications of less than 2 mm in diameter, without acoustic
shadow - and macrocalcifications (defined as all other types
of calcifications) without accompanying microcalcifications
(7b). The occurrence of the following sets of the features
was analysed:
A) >2UMRFs from the features 1–7 in 2 variants:
considering microcalcifications (A1) or all
calcifications (A2).
B) >2UMRFs from the features 1–7 excluding
pathological vascularization in 2 variants:
considering microcalcifications (B1) or all
calcifications (B2). Variant B1 corresponds to
category 4C (3 or 4 UMRFs) or 5 (5 UMRFs)
according to the thyroid imaging reporting and data
system (TIRADS) proposed by Kwak et al. [27].
These are the criteria for moderate (>50% - category
4C) and high (>90% - category 5) risk of malignancy.
C) presence of a solid hypoechoic nodule or a solid
hypoechoic component in a partially cystic nodule
(feature 3.) with one or more of the following
features: 4, 6, 7a. That is the criterion for high risk
of malignancy (>70%) adopted in the new ATA
recommendations [11] with exception of disrupted
rim calcifications, which were not assessed
separately in our study.
D) presence >2 UMRFs from features 1–2 and those
other features which would be significant in
predicting malignancy of FL.
Diagnostic efficacy of particular UMRFs and their sets
was analysed to differentiate between benign and malig-
nant nodules in patients with FL and UC.
Statistical analysis
The statistical analysis was performed with Statistica,
version 10 statistical software. The comparison of fre-
quency distributions was performed with χ2 test (with
modifications suitable for the number of analysed cases).
Kruskal-Wallis test was used for comparing continuous
variables between groups. Associations between US fea-
tures and malignancy were evaluated by using logistic
regression analysis, odds ratios (OR) with relative 95%
confidence intervals (95% CI) were calculated to determine
the relevance of all potential predictors of the outcome.
The effectiveness of UMRFs in the differentiation between
benign nodules and cancers was assessed by receiver oper-
ating characteristics curve (ROC) and the area under the
ROC (AUC) value analysis. Sensitivity (SEN), specificity
(SPC), positive predictive value (PPV), and negative predict-
ive value (NPV) were analysed for established UMRFs and
their sets. The percentage of nodules that satisfied evalu-
ated criteria or their sets were determined. The value of
0.05 was assumed as the level of significance.
The study design was approved by the Local Bioethics
Committee and all the patients gave their informed
consent.
Results
Table 1 shows demographic data of the examined patients
and the percentage of malignant neoplasms revealed in
postoperative histopathological examination in the FL and
UC groups. The histopathological examination confirmed
all unequivocal FNA results (BL and MN). Cytological
diagnosis of MN corresponded to 89 (89.0%) PTCs (in-
cluding 33/37.1% follicular variant of PTC), 9 (9.0%)
medullary cancers, 1 (1.0%) FTC oxyphilic type, 1 (1.0%)
undifferentiated carcinoma. In the group of FLUS nodules
eventual diagnoses were: 13 cancers (6.4%) including 9
(69.2%) PTCs (5/55.5% follicular variant of PTC), 3 (23.1%)
Table 1 Demographic data of the patients and the percentage of cancers revealed in the nodules with unequivocal and equivocal
FNA results
Parameter Category of FNA
UC FL
BL MN FLUS SFN
Number of patients 200 100 202 120
Age - mean ± SD [years] 53.7 ± 11.4 50.3 ± 14.1 52.8 ± 13.7 52.4 ± 14.9
Number (%) of males 13 (6.5) 8 (8.0) 19 (9.4) 15 (12.5)
Volume of nodules -mean ± SD [cm3] 8.5 ± 13.3 2.6 ± 4.6a 6.4 ± 12.6 5.3 ± 11.5
% of cancers in histopathological outcome 0 100 6.4 10.8
% of PTCs in malignant neoplasms 0 89.0 69.2 30.8
% of adenomas in histopathologically benign lesions 5.5 0 11.4 25.8
BL benign lesion, FL follicular lesion, FLUS follicular lesions of undetermined significance, MN malignant neoplasm, PTC papillary carcinoma, SFN suspicious for
follicular neoplasm, UC unequivocal cytology
ap < 0.01 MN vs BL; the distribution of small (<1 cm) nodules between UC and FL groups was even
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oxyphilic type of FTCs and 1 (7.7%) poorly differentiated
carcinoma. In the nodules diagnosed as SFN, the postoper-
ative examination showed 13 (10.8%) cancers including 4
(30.8%) PTCs (all follicular variant), 5 (38.5%) FTCs, 3
(23.1%) oxyphilic type of FTCs, and 1 (7.7%) undiffer-
entiated carcinoma. In total, PTCs constituted 50.0% of
all malignant neoplasms in the FL group and 89.0% of
all cancers in the MN group (p < 0.0001). Benign neo-
plasms were found in 11 (5.5%) nodules with cytological
diagnosis of BL – less often than in FLUS nodules - 23
(11.4%, p = 0.034) and in both those cytological groups
less often than in SFN nodules - 31 (25.8%, p < 0.0001
and p = 0.001, respectively). In the FL group adenomas
constituted 16.8% of all benign nodules (p < 0.0001 vs. BL).
Figure 1 shows differences in ultrasound image be-
tween FL and nodules with cytological diagnoses of BL
and MN. FL nodules were less often than BL, and more
often than MN, hypoechoic: 69.5 vs. 49.0% and 86.0%
(p < 0.0001 and p < 0.001, FL vs. BL and MN, respectively),
solid: 78.0 vs. 57.5% and 78.0% (p < 0.0001 and p < 0.001,
FL vs. BL and MN, respectively), both solid and hypoe-
choic: 55.3 vs. 31.5% and 80.0% (p < 0.0001 in both cases,
FL vs. BL and MN, respectively). Also, FL were less often
taller than wide than MN: 12.7 vs. 30.0% (p < 0.0001), and
less frequently contained any type of calcifications: 13.4 vs.
28.0% (p < 0.005) or microcalcifications: 5.0 vs. 13.0%
(p < 0.005). Suspected vascularization occurred more
often in FL than in BL: 21.7 vs. 7.0% (p < 0.0001). Irregular
margins were observed in FL occasionally, significantly
less often than in BL and MN: 6.2 vs 14.5% and 31.0%
(p < 0.005 and p < 0.0001, respectively).
Table 2 shows the incidence of particular UMRFs in
UC and FL nodules in relation to the histopathological
outcome: thyroid cancer vs. benign lesion. In the UC
group all UMRFs (features 1–7) occurred more often in
cancers than in benign nodules with the exception of
isolated macrocalcifications. In the FL group the only
feature more common in cancers than in benign nodules
was the presence of any type of calcifications: 34.6 vs.
11.5% (p = 0.001) as well as isolated macrocalcifications:
26.0 vs. 6.8% (p = 0.001), with no difference for micro-
calcifications. Noteworthy, taller than wide shape was
the closest to the threshold of significance of difference
between benign and malignant nodules in the FL group:
23.1 vs. 11.8% (p = 0.098). In FLUS nodules (Table 3)
UMRFs other than calcification and suspected shape oc-
curred slightly more often in cancers than in benign nod-
ules (the smallest differences were observed for irregular
margins). In SFN nodules hypoechogenicity and suspected
margins were observed slightly more often in benign nod-
ules, while hypoechogenicity of solid nodule, pathological
vascularization and microcalcifications were equally fre-
quent in benign and malignant nodules.
Logistic regression analysis confirmed that the pres-
ence of isolated macrocalcifications and the presence of
any type of calcifications were the only independent
UMRFs in differentiating between benign and malignant
FL nodules (Table 4). In the UC group the independent
features suggesting malignancy were hypoechogenicity,
solid echostructure, taller-than-wide shape, pathological
vascularization, and microcalcifications. Univariate ana-
lysis also showed the significance of suspected margins
and any type of calcifications, and demonstrated no sig-
nificance of isolated macrocalcifications.
Analysis of diagnostic efficacy of UMRFs (Table 5)
showed that in both groups solid echostructure and
hypoechogenicity had high SEN (UC: 94.0 and 86.0%, FL:
92.3 and 73.1%, respectively) and low SPC (UC: 42.5 and
51.0%, FL: 23.3 and 31.1%, respectively). More than 60% of
nodules in both groups presented with those features.
Other single features were found in at most 20% of UC
nodules and 21.7% of FL nodules. They had at least 85.5%
SPC in the UC group and at least 78.7% SPC in the FL
group, while SEN was low (13.0–31.0% in UC group and
3.8–34.6% in FL group). The lowest SEN was observed for
microcalcifications in the UC group and for irregular
Fig. 1 Comparison of UMRF’s incidence in ultrasound image of FL and UC (BL and MN) nodules. a – p < 0.0001 vs. FL. b – p < 0.005 vs. FL. BL - benign
lesion; FL – follicular lesion; MN - malignant neoplasm; UMRF: 1 - hypoechogenicity, 2 - solid echostructure, 3 - the features 1. and 2., 4 - taller-than-wide
shape, 5 - pathological vascularization, 6 - suspicious margins, 7 - calcifications, 7a – microcalcifications, 7b - macrocalcifications without
accompanying microcalcifications
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margins in the FL group. The PPV reached the highest
values for microcalcifications in the UC group (76.5%),
and for macrocalcifications in the FL group (25.9%)
(Table 5). The evaluation of single UMRFs was character-
ized in both groups by low or medium accuracy – AUC in
the range 0.5–0.7. In the FL group the highest AUC was
observed for the presence of any type of calcifications:
0.624 (0.489–0.759, CI95%, p = 0.071), and in the UC
group for the presence of solid, hypoechoic nodules: 0.749
(0.686–0.811, CI95%, p < 0.0001).
Tables 2 and 5 show data on the incidence and diag-
nostic efficacy of UMRFs sets in both groups. In the FL
Table 2 Comparison of the incidence of UMRFs and their sets in the nodules histopathologically benign and malignant in UC and
FL groups
Sonographic feature Category of FNA
UC (300) FL (322)










1 –hypoechogenicity 98/49.0 86/86.0 <0.0001 204/68.9 19/73.1 0.659
2 - solid echostructure 115/57.5 94/94.0 <0.0001 227/76.7 24/92.3 0.111
3 (1 & 2) - hypoechogenicity of solid nodule 63/31.5 80/80.0 <0.0001 161/54.4 17/65.4 0.279
4 - taller-than-wide shape 26/13.0 30/30.0 <0.0001 35/11.8 6/23.1 0.098
5 - pathological vascularization 14/7.0 19/19.0 <0.0001 63/21.3 7/26.9 0.504
6 - suspicious margins 29/14.5 31/31.0 <0.0001 19/6.4 1/3.8 0.922
7 – calcifications (micro or macro) 27/13.5 28/28.0 <0.0001 34/11.5 9/34.6 0.001
7a – microcalcifications 4/2.0 13/13.0 <0.0001 14/4.7 2/7.7 0.845
7b – isolated macrocalcifications 23/11.5 15/15.0 0.535 20/6.8 7/26.0 0.001
Sets of sonographic features
A1 - >2 UMRFs of: 1, 2, 4, 5, 6, 7a 30/15.0 55/55.0 <0.0001 71/24.0 8/30.8 0.441
A2 - >2 UMRFs of: 1, 2, 4, 5, 6, 7 40/20.0 63/63.0 <0.0001 79/26.7 12/46.2 0.035
B1 - >2 UMRFs of: 1, 2, 4, 6, 7a (TIRADS) 25/12.5 46/46.0 <0.0001 37/12.5 6/23.1 0.128
B2 - >2 UMRFs of: 1, 2, 4, 6, 7 33/16.5 53/53.0 <0.0001 46/15.5 10/38.5 0.003
C - 3 with 4 or 6 or 7a (ATA) 26/13.0 46/46.0 <0.0001 36/12.2 5/19.2 0.299
D - >2UMRFs of: 1, 2, 4, 7 20/10.0 43/43 <0.0001 37/12.5 10/38.5 0.001
Statistical significance was marked with bold type
FL follicular lesion, UC unequivocal cytology, UMRFs ultrasonographic malignancy risk features
Table 3 Comparison of the incidence of UMRFs and their sets in the nodules histopathologically benign and malignant in FLUS and
SFN groups
Sonographic feature Category of FNA
FLUS (202) SFN (120)










1 – hypoechogenicity 127/67.2 11/84.6 0.318 77/72.0 8/61.5 0.435
2 - solid echostructure 137/72.5 11/84.6 0.527 90/84.1 13/100.0 0.258
3 (1 & 2) -hypoechogenicity of solid nodule 94/49.7 9/69.2 0.299 67/62.6 8/61.5 0.939
4 - taller-than-wide shape 18/9.5 3/23.1 0.281 17/15.9 3/23.1 0.793
5 - pathological vascularization 37/19.6 4/30.8 0.539 26/24.3 3/23.1 0.806
6 - suspicious margins 13/6.9 1/7.7 0.651 6/5.6 0/0.0 0.839
7 – calcifications (micro or macro) 17/9.0 4/30.8 0.044 17/15.9 5/38.5 0.047
7a – microcalcifications 7/3.7 1/7.7 0.983 7/6.5 1/7.7 0.666
7b – isolated macrocalcifications 10/5.3 3/23.1 0.052 10/9.3 4/30.8 0.069
Statistical significance was marked with bold type
FL follicular lesion, UC unequivocal cytology, UMRFs ultrasonographic malignancy risk features
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Table 4 Results of logistic regression analysis in UC and FL nodules for particular UMRFs
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Statistical significance was marked with bold type
FL follicular lesion, UC unequivocal cytology
*multivariate analysis did not consider features 1 and 2 separately
**multivariate analysis did not consider features 7a and 7b separately
Table 5 Values of indexes describing the diagnostic efficacy of particular UMRFs and their sets in UC and FL nodules



















1 – hypoechogenicity 86.0 51.0 46.7 87.9 61.3 73.1 31.1 8.5 94.8 69.3
2 - solid echostructure 94.0 42.5 45.0 93.4 69.7 92.3 23.3 9.6 97.2 77.9
3 – (1 & 2)- hypoechogenicity of solid nodule 80.0 68.5 55.9 87.3 47.7 65.4 45.6 9.5 93.8 55.3
4 - taller-than-wide shape 30.0 86.5 53.6 71.3 18.7 23.1 88.2 14.6 97.8 12.7
5 - pathological vascularization 19.0 93.0 57.6 69.7 11.0 26.9 78.7 10.0 92.5 21.7
6 - suspicious margin 31.0 85.5 51.7 71.3 20.0 3.8 93.6 5.0 91.7 6.2
7 – calcifications (micro or macro) 28.0 86.5 50.9 70.6 18.3 34.6 88.5 20.9 93.9 13.4
7a – microcalcifications 13.0 98.0 76.5 69.3 5.7 7.7 95.3 12.5 98.7 5.0
7b – isolated macrocalcifications 15.0 88.5 39.5 67.6 12.7 26.9 93.2 25.9 93.6 8.4
Sets of sonographic features
A1 - >2 UMRFs of: 1, 2, 4, 5, 6, 7a 55.0 85.0 64.7 79.1 28.3 30.8 76.0 10.1 92.6 24.5
A2 - >2 UMRFs of: 1, 2, 4, 5, 6, 7 63.0 80.0 61.1 81.2 34.3 46.2 73.3 13.2 93.9 28.3
B1 - >2 UMRFs of: 1, 2, 4, 6, 7a (TIRADS) 46.0 87.5 64.8 76.4 23.7 23.1 87.5 14.0 92.8 13.4
B2 - >2 UMRFs of: 1, 2, 4, 6, 7 53.0 83.5 61.6 78.0 28.7 38.5 84.5 17.9 94.0 17.4
C - 3 with 4 or 6 or 7a (ATA) 46.0 87.0 63.9 76.3 24.0 19.2 87.8 12.2 92.5 12.7
D - >2 UMRFs of: 1, 2, 4, 7 43.0 90.0 66.2 75.9 21.0 38.5 87.5 21.3 94.2 14.6
FL follicular lesion, UC unequivocal cytology, UMRFs ultrasonographic malignancy risk features
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group the highest sum of SEN and SPC (38.5 and 87.5%,
respectively) and the highest PPV (21.3%) were found
for the set D composed of 2 features with high SEN:
hypoechogenicity and solid echostructure and 2 features
with high SPC: any type of calcifications and taller-than-
wide shape. The addition of suspected margins to that
set did not improve SEN (38.5%), and slightly lowered
SPC (84.5%) and PPV (17.9%). Further insertion of sus-
pected vascularization into the set increased SEN to
46.2%, but lowered SPC to 73.3%, and PPV to 13.2%.
The incidence of the sets of features including microcal-
cifications did not differ significantly between benign
and malignant nodules in the FL group. The set pro-
posed by the ATA (C) and the TIRADS set (B1) showed
SEN below 25% in the FL group, with SPC similar to
that of the set D. In the UC group, all the analysed sets
of UMRFs occurred more often in cancers than in be-
nign nodules (p < 0.0001 in all cases). Analysis of the sets
of UMRFs in the UC group allowed for approx. 1.5–5
time increase in SEN in comparison with the evaluation
of single features of low SEN, while keeping SPC in the
range of 80.0–90.0%. PPV exceeded 60% in the case of
all evaluated sets of features.
Table 6 shows the differences in ultrasound image of
malignant neoplasms from the UC and FL groups, as well
as benign nodules in those groups. Both cancers and
benign nodules in the FL group had suspected margins
less often than their counterparts from UC group – can-
cers: 3.8 vs. 31.0% (p = 0.010), benign lesions: 6.4 vs. 14.5%
(p = 0.003). Cancers in SFN subgroup were less often
hypoechoic than cancers in the MN subgroup: 61.5 vs.
86.0% (p = 0.026). Cancers of the FL group showed pres-
ence of all examined sets of UMRFs, which contained
microcalcifications (the sets A1, B, C, p < 0.05 in all cases)
less often than cancers of the UC group. Benign nodules
of the FL group were hypoechoic: 68.9 vs. 49.0%, solid:
76.7 vs. 57.5%, both solid and hypoechoic: 54.4 vs. 31.5%
and pathologically vascularized: 21.3 vs. 7.0% more often
than benign nodules of UC group (p < 0.0001 in all cases).
Those differences were significant also when benign nod-
ules of the FLUS and SFN subgroups were considered sep-
arately and compared to the UC group (p < 0.005 in all
cases). No significant differences were observed between
cancers of the FLUS and SFN subgroups. Benign nodules
in the SFN subgroup were more often solid and hypoe-
choic than benign nodules in the FLUS subgroup: 62.6 vs.
49.7% (p = 0.033).
Discussion
The aim of the study was the analysis of efficacy of
UMRFs evaluation in patients with FL. Data published
on this issue is less concordant than that referring to the
Table 6 Comparison of the incidence of UMRFs and their sets in malignant neoplasms and benign nodules in relation to the FNA
result – UC vs. FL
Sonographic feature Results of histopathological examinations
Benign Malignant










1 –hypoechogenicity 98/49.0 204/68.9 <0.0001 86/86.0 19/73.1 0.115
2 - solid echostructure (<25% cystic) 115/57.5 227/76.7 <0.0001 94/94.0 24/92.3 0.892
3 (1 & 2) -hypoechogenicity of solid nodule 63/31.5 161/54.4 <0.0001 80/80.0 17/65.4 0.115
4 -taller-than-wide shape 26/13.0 35/11.8 0.696 30/30.0 6/23.1 0.486
5 -pathological vascularization 14/7.0 63/21.3 <0.0001 19/19.0 7/26.9 0.374
6 - suspicious margins 29/14.5 19/6.4 0.003 31/31.0 1/3.8 0.010
7 –calcifications (micro or macro) 27/13.5 34/11.5 0.503 28/28.0 9/34.6 0.509
7a –microcalcifications 4/2.0 14/4.7 0.177 13/13.0 2/7.7 0.686
7b – isolated macrocalcifications 23/11.5 20/6.8 0.065 15/15.0 7/26.0 0.154
Sets of sonographic features
A1 - >2 UMRFs of: 1, 2, 4, 5, 6, 7a 30/15.0 71/24.0 0.015 55/55.0 8/30.8 0.028
A2 - >2 UMRFs of: 1, 2, 4, 5, 6, 7 40/20.0 79/26.7 0.087 63/63.0 12/46.2 0.119
B1 - >2 UMRFs of: 1, 2, 4, 6, 7a (TIRADS) 25/12.5 37/12.5 1.0 46/46.0 6/23.1 0.034
B2 - >2 UMRFs of: 1, 2, 4, 6, 7 33/16.5 46/15.5 0.775 53/53.0 10/38.5 0.187
C - 3 with 4 or 6 or 7a (ATA) 26/13.0 36/12.2 0.782 46/46.0 5/19.2 0.013
D - >2 UMRFs of: 1, 2, 4, 7 20/10.0 37/12.5 0.392 43/43.0 10/38.5 0.676
Statistical significance was marked with bold type
FL follicular lesion, UC unequivocal cytology, UMRFs ultrasonographic malignancy risk features
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usefulness of UMRFs analysis in the whole group of thyroid
nodules. However FL nodules are special, and in routine
cytological examinations there is no possibility to differenti-
ate between malignant and benign nodules, especially be-
tween FTC and adenoma [11, 20]. Such a group of nodules
raises expectations from ultrasound imaging. There is a
continuous search for features that could aid in making
clinical decisions and avoiding unnecessary surgical treat-
ment. This is of particular importance in populations simi-
lar to our own, characterized with a low risk of malignancy
in FL nodules and relatively high percentage of FTCs
among malignant tumours. In our study, FTCs amounted
to 46.2% of malignant neoplasms in the FL group. The per-
centage of PTCs among malignant nodules in FL group
was nearly 40% lower than in the group of unequivocal
diagnosis of MN. Among histopathologically benign nod-
ules, the incidence of follicular adenomas was 3 times
higher in the FL group than in the nodules with unequivo-
cal cytological diagnosis of BL.
Unfortunately, our data indicate that the evaluation of
UMRFs in such FLs is less effective, and its effectiveness
decreases parallel to the decrease in percentage of PTCs
among malignant neoplasms and to the increase of the
percentage of adenomas among benign nodules. In the
group of UC nodules all the examined UMRFs were found
more often in cancers than in benign nodules. Similar re-
sults were shown in the metaanalysis by Remonti et al. [8].
On the other hand, in the group of FL the features ob-
served more often in cancers than in benign lesions
included only calcifications of any type and macrocal-
cifications without accompanying microcalcifications.
In the FLUS subgroup, in which PTCs constituted
about 70% of all malignant neoplasms, other UMRFs
also occurred slightly more often in cancers. In con-
trast, in the SFN subgroup where the percentage of
PTC only slightly exceeded 30% and adenomas consti-
tuted above 25% of benign nodules, the relation was
reversed: hypoechogenicity, suspected margins, and - to a
lesser degree - hypoechogenicity of solid nodule and
pathological vascularisation were observed slightly more
often in benign nodules.
Our study suggests that the differences in the effect-
iveness of UMRFs assessment between the FL and UC
groups are the consequence of different ultrasound
image of both cancers and benign nodules between these
groups. Cancers in the FL group had suspected margins
less often than cancers in the UC group. Additionally,
cancers in the SFN subgroup were less frequently hypoe-
choic than cancers in the UC group. On the other hand,
benign nodules diagnosed cytologically as FLUS or SFN
were more often hypoechoic, solid as well as pathologic-
ally vascularized, and had suspected margins less often
than their counterparts with an unequivocal BL diagno-
sis. Other authors also reported the differences between
ultrasound images of FTCs and PTCs. Jeh et al. [22]
showed that FTCs usually had regular margins, were less
frequently hypoechoic and solid than PTCs, less often
presented suspicious shape or margins, and were not
characterized by microcalcifications. The follicular variant
of PTC, which more often corresponded to malignant
nodules in FL group than to those in MN group, causes
diagnostic difficulties, as it shows a higher rate of
follicular-like features than the conventional variant
[28, 29]. Thus, the obtained results cannot be surpris-
ing if one considers the fact that UMRFs have been
established mainly on the basis of ultrasound image of
the most common PTCs and are optimized for revealing
that type of thyroid cancer [27, 30].
Many reports on the usefulness of the UMRFs assess-
ment, both in unselected thyroid nodules and in FL nod-
ules, and particularly in nodules of the category III in the
Bethesda system, come from the countries with very high
iodine supply (e.g. South Korea). In such areas PTCs dom-
inate not only in the group of nodules with unequivocal
cytological diagnosis of MN, but also among FL nodules,
and especially in nodules of the category III in the Be-
thesda system [6, 14–16, 19]. The percentage of PTCs in
this category is further increased by frequent classification
into this category of the nodules with borderline cyto-
logical result, when characteristic features of benign and
malignant lesions coexist in a smear and the cellularity of
the aspirate is scant. Consequently, at some centres the
frequency of formulating FNA diagnoses of the category
III reaches up to 20% (instead of assumed 5–7%). Add-
itionally, the malignancy risk related to this category
approaches 50% (instead of assumed 5–15%) [31–35],
and the percentage of PTCs among malignant neo-
plasms in this category is over 90% [6, 14–16, 19]. In
such centres, the effectiveness of the UMRFs assess-
ment in the category III of FNA results is high. In the
study by Jeong et al. [14] diagnostic usefulness of evalu-
ating taller-than-wide shape, ill-defined margins, and
microcalcifications or macrocalcifications was shown in
the Bethesda category III nodules. Yoo et al. [19] showed
that malignancy in the nodules of that category was asso-
ciated with taller-than-wide shape, ill-defined margins and
marked hypoechogenicity, while Gweon et al. [15] re-
ported that it was related to marked hypoechogenicity,
microlobulated or irregular margins, microcalcifications,
and taller-than-wide shape. Kim et al. [16] showed that
the presence of several (>1) UMRFs of the following:
marked hypoechogenicity, a spiculated margin, microcalci-
fications, and a taller-than-wide shape in solid thyroid Be-
thesda III nodules, is an indication for surgical treatment
without a control FNA. In all these studies, the risk of
malignancy in the nodules with the category III in the
Bethesda system and suspicious ultrasound image was
significantly higher when compared with cytological
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evaluation alone. But in none of the above mentioned
studies the risk of malignancy in Bethesda III nodules
was assessed with consideration for whether the examined
nodules were on the borderline between benign lesions
and follicular neoplasms (nodules defined as classic FLUS
with atypia of cellular architecture) or on the borderline
between benign nodules and cancers (nodules with nu-
clear atypia – atypia of undetermined significance (AUS).
Many authors use this distinction and indicate that the
AUS subgroup is characterized by a higher than FLUS risk
of malignancy, a higher percentage of PTCs among malig-
nant neoplasms [9, 36–39] and a specific ultrasound
image. Lee et al. [4] found that the AUS group more fre-
quently had non-circumscribed margins and taller-than-
wide shape than the FLUS group. The incidence of FTCs
was significantly higher in the FLUS group than in the
AUS group (33.3 vs.1.6%) [4]. Similarly, Choi et al. [38]
found that a spiculated margin, marked hypoechogenicity,
and micro- or macrocalcifications were significantly more
common in AUS than in FLUS. Interestingly, in the report
from Turkey, where the risk of malignancy in Bethesda III
thyroid nodules is lower (22.8%) than in the above
mentioned reports from South Korea, the only predictive
features of malignancy were hypoechogenicity in the AUS
group and peripheral vascularization in the FLUS group
[2]. In the report from Brazil, with a similar risk of malig-
nancy in Bethesda III thyroid nodules (22.6%), Rosario [9]
showed that AUS presented a higher frequency of suspi-
cious malignant US findings compared to FLUS, but
evaluation of UMRFs allowed to predict malignancy both
in AUS and FLUS nodules. However, in that study PTCs
also constituted 91.2% of all malignant tumours.
In our study the nodules of the Bethesda category III
were dominated by FLUS diagnoses. Only in 2.1% of
cases the smear was classified into this category because
of the presence of nuclear atypia – corresponding to AUS.
It can be explained by epidemiological circumstances and
a continued high incidence of non-neoplastic thyroid nod-
ules in our patients. But it may also be the consequence of
a more conservative attitude to the rules for formulation
of FLUS diagnosis, which was limited to nodules from the
boundary between follicular neoplasms and benign le-
sions. Consequently, the percentage of PTCs among ma-
lignant neoplasms was lower in our study (70%) and it
could decrease the effectiveness of UMRFs evaluation.
In the case of the category IV of cytological diagnoses –
SFN – the effectiveness of UMRFs analysis was even
lower, as mentioned before. Recent reports seldom refer to
this particular group of cytological diagnoses. This is the
consequence of clinical recommendations that imply sur-
gical treatment in such cases. Moreover, many previous
reports showed that the evaluation of UMRFs was not
useful in that category of cytological diagnoses [17]. Re-
cently, Iskandar et al. [18] analysed joint groups III and IV
of cytological diagnoses and found that in such a group of
nodules the examined UMRFs (microcalcifications, irregu-
lar borders, hypervascularity and hypoechogenicity) were
not associated with malignancy. The malignancy rate in
resected thyroid nodules was 13% for Bethesda III and
28% for Bethesda IV, PTCs constituted 72% of malignant
neoplasms. Park et al. [7] found that in the category IV
the evaluation of UMRFs had the lowest efficiency in the
comparison with other groups of cytological diagnoses
(the risk of malignancy in that group was 5.7%). On the
other hand, in the group of nodules of the IV diagnostic
category and with 24.3% overall malignancy rate Chng et
al. [1] showed the usefulness of assessing irregular mar-
gins, hypoechogenicity, and taller-than-wide shape, despite
the fact that the percentage of PTCs among malignant
neoplasms was below 50% in that study. However, a no-
ticeable amount (40%) of the patients in that group were
not treated surgically.
In our study only the presence of macrocalcifications
or any type of calcifications (which obviously included
macrocalcifications) increased the risk of malignancy in
FL nodules (both FLUS and SFN) in comparison with
cytological evaluation alone to the values >15% (PPV for
any type of calcifications - 25.9%, and for macrocalcifica-
tions - 20.9%), which is a threshold commonly assumed
in the recommendations above which the surgical treat-
ment is advocated. Only slightly lower PPV (14.6%) was
found for taller-than-wide shape. Similar PPV values
were obtained for the set of UMRFs including 2 features
with high SEN: hypoechogenicity, solid echostructure
and 2 features with high SPC: calcifications of any type
and suspected shape. That set showed nearly 90% SPC
and SEN higher than the assessment of calcifications
alone. Higher SEN was also observed in all the examined
sets which included calcifications of any type. The sets
of features which included only microcalcifications were
less effective in the FL group, and the incidence of such
sets was similar in benign and malignant nodules in that
group. The lowest values were observed for the set pro-
posed by the ATA and the TIRADS set. But both those
sets are tailored to reveal the most common PTCs. The
TIRADS set was specified by Kwak in the group of
nodules with unequivocal cytological result after ex-
cluding nodules with indeterminate cytology [27] and
verified against the group of cancers with a low per-
centage of FTCs (1.7%) and low percentage of follicular
variant of PTCs (2.5%) [40]. Papillary cancers amounted
to more than 95% of malignant neoplasms in that
study. The authors found in such a group of thyroid
nodules that the presence of macrocalcifications with-
out accompanying microcalcifications was not useful
diagnostically [27], what is in concordance with our ob-
servations in the group of nodules with unequivocal
cytology.
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Recently, several papers have been published on the
evaluation of TIRADS in FL nodules. Yoon et al. [10]
found significant differences in TIRADS category between
benign and malignant nodules in the AUS subgroup, but
not in the FLUS subgroup. In the group of nodules with
FLUS in cytological result PTCs amounted to 57% of ma-
lignant neoplasms while in the AUS group - 100%. Park et
al. [6] analysed the usefulness of TIRADS in nodules with
two AUS/FLUS results and found that ultrasound features
and TIRADS categories did not differ between benign
and malignant nodules. Maia et al. [5] evaluated the
usefulness of the TIRADS system in Bethesda categor-
ies III, IV and V with positive conclusions, but they
used the modified version of the system with the
addition of vascularity criteria by Doppler analysis. Also
in that study, PTCs constituted nearly 90% of all malig-
nant neoplasms. On the other hand, Chng et al. [1]
showed the usefulness of TIRADS scores 4C and 5 in
predicting malignancy of category IV nodules, but that
study had retrospective design and nearly half of the
patients did not have histological results.
In the UC group the analysis of all the sets of UMRFs
increased SEN as much as several times in comparison
with the evaluation of single features with low SEN,
while preserving high SPC. PPV exceeded 60% for all
the examined sets of features. But direct comparison of
PPV between the UC and FL groups, as well as between
our study and the reports from other centres is not
possible. PPV of UMRFs depends on the malignancy
rate of nodules in a particular diagnostic category. Thus
special attention should be paid while interpreting PPV
in the case of cytological category III, where the risk of
malignancy ranges widely from 5 to 50% [31–35].
Other factors, which make comparison of the reported
results difficult, are independent of the examined popu-
lation, but are related to the expertise of the person
performing the examination and the type of ultrasono-
graph used. Qualitative and not quantitative character
of UMRFs makes them more susceptible for variable
interpretation by ultrasonographers, especially when
they come from different centres and work with differ-
ent equipment. Another issue is the variable way of de-
fining analysed features, e.g. solid character of a nodule
is assumed when the solid part of a nodule is greater
than 50% [4] or 90% [40]. In some ultrasonographs
additional software is used that facilitates visualisation
of some UMRFs, e.g. microcalcifications characteristic
of PTCs. It should be stressed that the assessment of
microcalcifications is not an easy task. Bright reflec-
tions on ultrasound imaging in spongiform nodules
may be confused with microcalcifications by less profi-
cient sonographers [11]. Thus, in our study all exami-
nations were performed by experienced ultrasongraphers
with the same equipment.
Another important advantage of our study is performing
UMRFs evaluation directly prior to biopsy. Therefore, the
result of FNA did not influence that evaluation. We also
limited our analysis to nodules verified with postoperative
histopathological examination. Such a design has both ad-
vantages (certainty of the correct diagnosis of benign and
malignant lesions) and disadvantages (a bias introduced by
the additional selection of nodules). But in our material
the difference in the risk of malignancy in FLUS nodules,
as determined by histopathological examination and cyto-
logical follow-up, is not big (<3%) [25]. Our previous study
also showed that there were no differences in the ultra-
sound image of FLUS nodules in the patients treated sur-
gically and conservatively. Patients treated surgically were
younger and had larger nodules [25]. A disadvantage of
our study is the relatively low number of cancers in the FL
group, but it reflects the frequency of cancers in this cyto-
logical category in our population. Undoubtedly, extension
of the study for a larger group of patients would be indi-
cated. From the methodological point of view the ideal
study design would compare the effectiveness of URMF
analysis between iodine sufficient and iodine deficient
populations. However such an assessment would meet
practical difficulties in securing uniform URMF assess-
ment in two geographically remote study groups.
Conclusions
Summing up, in FL nodules with low risk of malignancy
and high percentage of FTCs among malignant neo-
plasms the evaluation of single UMRFs, as well as their
sets, shows lower efficiency than in the group of nodules
with unequivocal diagnosis of BL or MN. However, the
presence of macrocalcifications in the nodule justifies
surgical treatment. The effectiveness of UMRFs evaluation
in FL decreases parallel to the decrease in percentage of
PTCs among malignant neoplasms and to the increase of
the percentage of adenomas among benign nodules. The
ultrasound image of follicular neoplasms differs from the
image of PTCs. Thus, comparisons of the results obtained
in various centres on the discussed issue are not justified
without consideration for epidemiological differences be-
tween examined populations and for the differences in the
way of classification of the aspirates into diagnostic cat-
egories corresponding to FL.
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